Skin toxicity is the most common adverse reaction observed with epidermal growth factor receptor (EGFR) inhibitors and checkpoint inhibitors such as anti-CTLA4 agents (T-lymphocyte-associated antigen 4) and anti-PD-1 agents (programmed cell death protein-1). The gene discussed is EGFR; the disease is toxicity.